---
title: "300723.SZ (300723.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300723.SZ/news.md"
symbol: "300723.SZ"
name: "300723.SZ"
parent: "https://longbridge.com/en/quote/300723.SZ.md"
datetime: "2026-05-22T00:09:20.949Z"
locales:
  - [en](https://longbridge.com/en/quote/300723.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300723.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300723.SZ/news.md)
---

# 300723.SZ (300723.SZ) — Related News

### [ApicHope's subsidiary has obtained the registration certificate for aminohexanoic acid injection](https://longbridge.com/en/news/287204745.md)
*2026-05-21T10:52:04.000Z*
> ApicHope's wholly-owned subsidiary, Guangzhou ApicHope Pharmaceutical Co., Ltd., recently obtained the registration cert

### [ApicHope: AR882 is undergoing a critical Phase III clinical trial and is still in the clinical research stage](https://longbridge.com/en/news/286870235.md)
*2026-05-19T07:19:03.000Z*
> ApicHope stated on the interactive platform on May 19 that currently, AR882 is undergoing a critical Phase III clinical 

### [](https://longbridge.com/en/news/286527433.md)
*2026-05-15T07:54:16.000Z*
> The National Healthcare Security Administration issued implementation opinions on reforming and improving the supply gua

### [ApicHope performance briefing: The clinical trial progress of the gout innovative drug AR882 phase III is going smoothly](https://longbridge.com/en/news/285377939.md)
*2026-05-06T12:28:36.000Z*
> On the afternoon of May 6th, ApicHope (300723) held an online performance briefing for the year 2025. Recently, ApicHope

### [ApicHope earnings conference: The domestic Phase III clinical trial of AR882 is expected to be completed in June this year](https://longbridge.com/en/news/284531986.md)
*2026-04-29T09:11:48.000Z*
> On April 29th, ApicHope (300723) disclosed a record of investor relations activities. The company held a performance bri

### [Over 30 pharmaceutical companies released their Q1 reports: some made huge profits while others incurred losses, intensifying industry differentiation](https://longbridge.com/en/news/284207900.md)
*2026-04-27T11:34:10.000Z*
> The financial reports of the A-share pharmaceutical sector for the first quarter show an increasing divergence in the in

### [ApicHope: Annual R&D investment exceeds 200 million yuan, potential new drugs highly recognized by capital](https://longbridge.com/en/news/284141075.md)
*2026-04-27T01:32:54.000Z*
> ApicHope released its 2025 annual report and the first quarter report for 2026, with a revenue of 932 million yuan in 20

### ["A-Share Focus" ApicHope once rose over 12%, with net profit in the first quarter soaring more than 9 times](https://longbridge.com/en/news/283941754.md)
*2026-04-24T05:57:00.000Z*
> Biopharmaceutical company ApicHope (Shenzhen: 300723) saw its stock price rise over 12% at one point, currently up 8.94%

### [The chemical formulation sector has seen a short-term surge](https://longbridge.com/en/news/283923512.md)
*2026-04-24T02:35:08.000Z*
> The chemical formulation sector saw a short-term surge, with GOLDSTONE ASIA PHARM and ApicHope rising over 10%, while GL